Education
About Us
Working with TipRanks
Follow Us
Renalytix (GB:RENX)
LSE:RENX
RENX Stock Chart & Stats
5.90p
0.99p(8.62%)
At close: 4:00 PM EST
5.90p
0.99p(8.62%)
Day’s Range― - ―
52-Week Range3.50p - 15.50p
Previous CloseN/A
Volume11.59K
Average Volume (3M)10.03M
Market Cap
£15.84M
Enterprise Value26.40M
Total Cash (Recent Filing)£9.63M
Total Debt (Recent Filing)£8.21M
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding437,018,680
10 Day Avg. Volume3,807,103
30 Day Avg. Volume10,033,489
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Diagnostic PlatformRenalytix's KidneyIntelX is a focused, differentiated product combining biomarkers, clinical data and ML algorithms. This integrated diagnostic approach creates a durable technical and clinical barrier to entry, supporting longer-term adoption by providers and potential integration into care pathways.
Improving Gross MarginThe sharp improvement in gross margin alongside ~26% revenue growth suggests the test's unit economics are improving as volumes rise or costs fall. Sustained margin expansion would underpin scalable profitability as adoption grows, making future operating leverage more attainable over months.
Reduced Cash Burn TrajectoryOperating and free cash flow improved meaningfully year-over-year, cutting cash burn roughly in half. This trend reflects progress on cost control or revenue traction and extends runway absent immediate financing, improving the company's ability to execute strategic initiatives over the medium term.
Bears Say
Negative Equity / Stressed Balance SheetNegative shareholders' equity signals capital depletion and constrains financial flexibility. It typically implies reliance on external financing, heightens dilution or creditor risk, and limits ability to make strategic investments without fresh capital—a persistent balance-sheet constraint.
Large Ongoing LossesDespite revenue and margin improvements, net and operating losses remain very large relative to scale. Sustained heavy losses mean continued dependence on funding, constrain reinvestment, and create execution risk if commercial uptake or reimbursement progress stalls.
Very Small Revenue BaseWith about $3m of revenue, the business is still nascent and unable to absorb fixed costs or demonstrate durable scale economics. Structural success requires materially higher test volumes and sustained payor coverage to convert improved unit metrics into reliable, self-funded growth.
Renalytix News
RENX FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest share price was 3.50p and its highest was 15.50p in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is £15.84M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Mar 26, 2026 which is in 23 days.
How were Renalytix’s earnings last quarter?
Currently, no data Available
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 437,018,680 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in GB:RENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Proteome Sciences
―
Verici Dx Plc
―
Options Prices
Currently, No data available
---